Key result
Detectable brown adipose tissue was associated with a lower abdominal fat to total fat ratio (0.28 vs 0.31, P=0.01) and higher liver density (51.3 vs 47.1 HU, P=0.003) compared to matched controls.
Why the study?
Is the presence of brown adipose tissue detected by PET/CT associated with less central obesity in adult oncology patients?
Case-Control (n=111)
Single-blind (outcome assessor)
Is the presence of brown adipose tissue detected by PET/CT associated with less central obesity in adult oncology patients?
Absolute Event Rate: 0.28% vs 0.31%
p-value: p=0.01
Active brown adipose tissue detected by F-FDG PET/CT is associated with less central obesity and liver fat, suggesting a potential protective effect against features of the metabolic syndrome.
BAT on PET/CT was associated with less central and liver fat in oncology patients; leaves open protective metabolic role pending prospective data.
PURPOSE: This retrospective review was performed to determine whether patients with brown adipose tissue (BAT) detected by fluorine-18-fluorodeoxyglucose (F-FDG) PET/computed tomography (CT) imaging have less central obesity than BMI-matched control patients without detectable BAT. PATIENTS AND METHODS: Thirty-seven adult oncology patients with F-FDG BAT uptake were retrospectively identified from PET/CT studies from 2011 to 2013. The control cohort consisted of 74 adult oncology patients without detectable F-FDG BAT uptake matched for BMI/sex/season. Tissue fat content was estimated by CT density (Hounsfield units) with a subsequent noise removal step. Total fat and abdominal fat were calculated. An automated separation algorithm was utilized to determine the visceral fat and subcutaneous fat at the L4/L5 level. In addition, liver density was obtained from CT images. CT imaging was interpreted blinded to clinical information. RESULTS: There was no difference in total fat for the BAT cohort (34±15 l) compared with the controls (34±16 l) (P=0.96). The BAT cohort had lower abdominal fat to total fat ratio compared with the controls (0.28±0.05 vs. 0.31±0.08, respectively; P=0.01). The BAT cohort had a lower visceral fat/(visceral fat+subcutaneous fat) ratio compared with the controls (0.30±0.10 vs. 0.34±0.12, respectively; P=0.03). Patients with BAT had higher liver density, suggesting less liver fat, compared with the controls (51.3±7.5 vs. 47.1±7.0 HU, P=0.003). CONCLUSION: The findings suggest that active BAT detected by F-FDG PET/CT is associated with less central obesity and liver fat. The presence of foci of BAT may be protective against features of the metabolic syndrome.
No takes yet. Share an insight, caveat, or question.
Green et al. (2017) conducted a case-control in Oncology (n=111). Detectable brown adipose tissue (BAT) vs. Matched controls without detectable BAT was evaluated on Abdominal fat to total fat ratio (p=0.01). Detectable brown adipose tissue was associated with a lower abdominal fat to total fat ratio (0.28 vs 0.31, P=0.01) and higher liver density (51.3 vs 47.1 HU, P=0.003) compared to matched controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: